Cannabis Science Ramps Up Cancer Studies, Product Releases Following NCI Reports

- September 28th, 2015

Cannabis Science Inc. (OTCMKTS:CBIS) announced that it is ramping up its cancer studies and product releases in response to the National Cancer Institutes initiatives to raise awareness about cancer studies and education about cancer.

Cannabis Science Inc. (OTCMKTS:CBIS) announced that it is ramping up its cancer studies and product releases in response to the National Cancer Institutes initiatives to raise awareness about cancer studies and education about cancer.
As quoted in the press release:

The Company is focused on persuading governments and individuals across the world to expand their preventive and therapeutic actions against Cancer and other critical ailments. Cannabis Science is highly motivated to accelerate the pace of its cancer drug development studies and is ramping up its new products distribution to the California market immediately through additional product releases and additional licensing deals in each state-by-state regulated market and its formal FDA initiatives.
Cannabis Science has successfully released its first group of cannabinoids in California for test marketing and the positive results have been assessed as indicators to ramp up distribution and continue adding products, including pills, extracts, and creams, hiring of additional representatives and additional locations for a much larger products release. The CBIS Brand is currently being sold in multiple locations in California that are State licensed public and private cannabis dispensaries.

Raymond Dabney, president, CEO and co-founder of Cannabis Science, commented:

Our previous success with self-medicated patient usage is a great building block for us as our increasing requests for new products from self-medicating patients and dispensaries indicate. As we already know, affected people are looking for cannabinoid treatments for all types of acute and chronic illnesses. Cancer is just one of our major targets, and building from our previous success, we are ramping up production to start fulfilling that demand. Our patient-centered outcomes program, the Patient Access Center (PAC), will use extensive feedback from patients to inform our drug development efforts. In addition, the PAC will become a critical tool in our drug development cycle.
We have and are releasing many diverse products for many different disorders that reflect the particular circumstances of each self-medicating patient. We will be releasing various products, with varying dosages and delivery methodologies, in various jurisdictions as regulatory stipulations permit. We look forward to releasing more information about additional products and locations as the information becomes available. Please feel free to contact me directly with any questions and special requests; our team is ready.

Click here to read the full Cannabis Science Inc. (OTCMKTS:CBIS) press release.

Get the latest Cannabis Investing stock information

Leave a Reply